The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EXEL | +6.05% | +92.36% | +13.98% | +170% |
| S&P | +16.53% | +80.89% | +12.59% | +354% |
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $598.66M | 5.6% |
| Gross Profit | $572.18M | 4.6% |
| Gross Margin | 95.58% | -0.9% |
| Market Cap | $11.75B | 23.6% |
| Market Cap / Employee | $10.91M | 0.0% |
| Employees | 1.1K | -6.1% |
| Net Income | $244.53M | 74.8% |
| EBITDA | $242.86M | 41.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $416.10M | 196.9% |
| Accounts Receivable | $286.92M | 8.1% |
| Inventory | 21.7 | -3.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $173.04M | -9.3% |
| Short Term Debt | $27.88M | 11.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 26.67% | 9.2% |
| Return On Invested Capital | 10.54% | 0.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $332.36M | 40.7% |
| Operating Free Cash Flow | $333.52M | 38.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 15.68 | 22.13 | 16.88 | 15.66 | -18.31% |
| Price to Book | 4.63 | 5.69 | 5.49 | 5.44 | 30.03% |
| Price to Sales | 4.33 | 5.89 | 4.88 | 5.19 | 12.89% |
| Price to Tangible Book Value | 4.77 | 5.86 | 5.66 | 5.60 | 30.23% |
| Price to Free Cash Flow TTM | 12.14 | 17.41 | 14.32 | 13.75 | -7.40% |
| Enterprise Value to EBITDA | 46.95 | 56.64 | 39.25 | 46.06 | -13.18% |
| Free Cash Flow Yield | 8.2% | 5.7% | 7.0% | 7.3% | 7.99% |
| Return on Equity | 30.2% | 29.0% | 30.6% | 35.5% | 53.62% |
| Total Debt | $187.13M | $179.84M | $176.46M | $200.92M | -6.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
